At GeneTex, we embrace the privilege of contributing to this relentless campaign against human disease. We understand that meaningful advances in biomedical research depend on reliable antibodies and other reagents, and we work constantly to improve our product design, manufacturing, and validation. GeneTex is presently shifting the majority of its productive capacity to the development of recombinant antibodies, in part due to the well-documented challenges associated with polyclonal and even hybridoma-generated monoclonal antibodies. In addition, the Company has expanded its antibody validation efforts to include a “Five-Pillar Validation” strategy that will markedly enhance our present quality assurance protocols. A major focus of this strategy is a greater reliance on definitive knockout/knockdown testing of antibodies. We are also actively seeking opportunities to incorporate our best-characterized recombinant antibodies into clinical diagnostic and point-of-care platforms to more directly assist medical decision-making.
In order for these goals to be realized, significant financial, infrastructure, and personnel commitments by the GeneTex management were necessary over the last several years. These investments are now paying functional dividends with the recombinant antibody production apparatus and the enhanced validation protocols fully established. This will allow GeneTex to rapidly create the necessary reagents to fight not only centuries-old diseases, but also those in the future.
We appreciate your support and patronage, and we always welcome your input.
Thank you for your research!